下一代测序指导下的聚（ADP-核糖）聚合酶抑制剂疗法治疗BRCA2突变的转移性子宫平滑肌肉瘤 - Suppr

Suppr

超能文献

Next-Generation Sequencing-Guided Treatment of BRCA2-Mutant Metastatic Uterine Leiomyosarcoma With Poly(ADP-ribose) Polymerase Inhibitor Therapy.

作者信息

Kirkendoll Cameron, Mansour Richard, Gaddam Shiva Jashwanth

机构信息

Department of Hematology and Oncology, LSU Health Sciences, Shreveport, LA.

出版信息

JCO Precis Oncol. 2024 Dec;8:e2400401. doi: 10.1200/PO-24-00401. Epub 2024 Dec 12.

DOI:10.1200/PO-24-00401

PMID:39666931

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11658017/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/11658017/48f98c291993/po-8-e2400401-g001.jpg

相似文献

Next-Generation Sequencing-Guided Treatment of BRCA2-Mutant Metastatic Uterine Leiomyosarcoma With Poly(ADP-ribose) Polymerase Inhibitor Therapy.下一代测序指导下的聚（ADP-核糖）聚合酶抑制剂疗法治疗BRCA2突变的转移性子宫平滑肌肉瘤

JCO Precis Oncol. 2024 Dec;8:e2400401. doi: 10.1200/PO-24-00401. Epub 2024 Dec 12.

Functional Loss Defines a Targetable Subset in Leiomyosarcoma.功能性丧失定义了平滑肌肉瘤的一个可靶向亚群。

Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.

Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.通过前瞻性临床测序定义的子宫肉瘤基因组景观。

Clin Cancer Res. 2020 Jul 15;26(14):3881-3888. doi: 10.1158/1078-0432.CCR-19-3959. Epub 2020 Apr 16.

Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.BRCA2/TP53/PTEN 缺失型转移性子宫平滑肌肉瘤对奥拉帕利的快速反应：一例报告。

Perm J. 2021 May;25. doi: 10.7812/TPP/20.251.

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.同时存在 BRCA2/SPOP 突变可预测转移性去势抵抗性前列腺癌对聚（ADP-核糖）聚合酶抑制剂的敏感性。

Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9.

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.BRCA1/2 种系和体细胞突变景观在高级别浆液性卵巢癌患者中的分析。

BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.

Retrospective Analysis of -Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.聚（ADP-核糖）聚合酶抑制剂治疗α改变子宫肉瘤的回顾性分析

JCO Precis Oncol. 2025 Mar;9:e2400765. doi: 10.1200/PO-24-00765. Epub 2025 Mar 21.

Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.BRCA2 改变在子宫平滑肌肉瘤中的临床可操作性：一个分子肿瘤委员会病例报告和 cBioPortal 综合分析。

Oncologist. 2024 Jul 5;29(7):560-565. doi: 10.1093/oncolo/oyae082.

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.多聚 BRCA2 突变继发于卡铂治疗后，导致 mCRPC 患者对 PARP 抑制剂芦卡帕利产生耐药：病例报告。

BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.聚（ADP - 核糖）聚合酶 -1抑制剂治疗可使原位Brca2/p53突变乳腺肿瘤在体内消退，并与卡铂联合使用可延缓肿瘤复发。

Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21.

本文引用的文献

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).奥拉帕利和替莫唑胺治疗晚期子宫平滑肌肉瘤的 II 期研究（NCI 方案 10250）。

J Clin Oncol. 2023 Sep 1;41(25):4154-4163. doi: 10.1200/JCO.23.00402. Epub 2023 Jul 19.

Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic mutation.聚（ADP-核糖）聚合酶（PARP）抑制剂在存在体细胞突变的复发性子宫平滑肌肉瘤中的临床应用。

Gynecol Oncol Rep. 2022 Jul 14;42:101044. doi: 10.1016/j.gore.2022.101044. eCollection 2022 Aug.

Colorectal leiomyosarcoma with mutation benefit from treatment with olaparib: a case report.携带特定突变的结直肠平滑肌肉瘤对奥拉帕利治疗有效：一例报告

J Gastrointest Oncol. 2022 Jun;13(3):1499-1504. doi: 10.21037/jgo-22-419.

Perm J. 2021 May;25. doi: 10.7812/TPP/20.251.

Prevalence and occult rates of uterine leiomyosarcoma.子宫平滑肌肉瘤的患病率及隐匿率

Medicine (Baltimore). 2020 Aug 14;99(33):e21766. doi: 10.1097/MD.0000000000021766.

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。

J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.

A decade of clinical development of PARP inhibitors in perspective.PARP 抑制剂十年临床开发透视。

Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192.

Functional Loss Defines a Targetable Subset in Leiomyosarcoma.功能性丧失定义了平滑肌肉瘤的一个可靶向亚群。

Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.

Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.子宫平滑肌肉瘤的预后和治疗：国家癌症数据库研究。

Gynecol Oncol. 2017 Apr;145(1):61-70. doi: 10.1016/j.ygyno.2017.02.012. Epub 2017 Mar 15.

Hallmarks of cancer: the next generation.癌症的特征：下一代。

Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验